your market intelligence analyst
Search Results
138 results
Your search is now limited to «Sulfonylureas» expert search.
FeedNavigator (EU) 10/17/2019 07:38
Evidence suggests that antidiabetic drug dipeptidyl-peptidase 4 (DPP-4) inhibitors may be able to attenuate albuminuria, whereas the influence of sulfonylureas on albuminuria remains unclear.
More from FeedNavigator (EU):
Seed Today 10/15/2019 15:58
Analysts from the Buenos Aires Grains Exchange informed that Argentinian farmers are increasing the use of sulfonylurea-tolerant soybeans (STS) varieties, a non-GMO trait that confers to the crop with tolerance to certain ALS-inhibitor herbicides.
More from Seed Today:
Healio News 10/15/2019 15:42
Besides the standard metformin therapy, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-IV inhibitors, insulin and sulfonylureas are among the types of medications that physicians can choose from when selecting treatment strategies for patients with type 2 diabetes, he said.
More from Healio News:
Data from long-term clinical trials of rosiglitazone versus other antidiabetes agents (metformin or sulfonylureas), including a cardiovascular outcome trial (RECORD), observed no difference in overall mortality or in major adverse cardiovascular events (MACE) and its components.
More from RxList - New & Updated Drug Monographs:
Diabetes In Control News 10/14/2019 20:07
Efpeglenatide, a new GLP-1 receptor agonist, referenced to liraglutide in Phase II trial. .
More from Diabetes In Control News:
Acquisition is expected to realize over $10M in annual synergies. Results in Currax owning the global rights to CONTRAVE®. In connection with this transaction, Currax repaid 25% of its outstanding debt. Currax anticipates revenues in excess of $1... Biopharmaceuticals, Mergers & Acquisitions Currax Pharmaceuticals, Nalpropion Pharmaceuticals, CONTRAVE.
More from Healthcare Sales & Marketing Network: 09/25/2019 08:32
... recommended first-line drug therapy for Type 2 diabetes, is associated in the new study with 20 percent decreased risk of major adverse cardiovascular events when compared to a class of common diabetes drugs called sulfonylureas.
More from
diaTribe 09/20/2019 08:29
The FDA currently has a product-label warning for heart-related death for all sulfonylureas.
More from diaTribe:
Medical Xpress - Diabetes 09/19/2019 13:10
(HealthDay)—Linagliptin is noninferior to glimepiride for adults with relatively early type 2 diabetes and elevated cardiovascular risk, according to a study published online Sept. 19 in the Journal of the American Medical Association to coincide with the annual meeting of the European Association for the Study of Diabetes, held from Sept. 16 to 20 in Barcelona, Spain.
More from Medical Xpress - Diabetes:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications